A Response to: Letter to the Editor Regarding “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”

This communication seeks to address the questions of Dhere and colleagues in their letter on our study “Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) versus lower-valent alternatives in Filipino infants.” We hope to provide clarity on each of the three potential misunder...

Descripción completa

Detalles Bibliográficos
Autores principales: Perdrizet, Johnna, Horn, Emily K., Nua, Winniefer, Perez-Peralta, Judith, Nailes, Jennifer, Santos, Jaime, Ong-Lim, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124259/
https://www.ncbi.nlm.nih.gov/pubmed/35474191
http://dx.doi.org/10.1007/s40121-022-00639-3
_version_ 1784711703876861952
author Perdrizet, Johnna
Horn, Emily K.
Nua, Winniefer
Perez-Peralta, Judith
Nailes, Jennifer
Santos, Jaime
Ong-Lim, Anna
author_facet Perdrizet, Johnna
Horn, Emily K.
Nua, Winniefer
Perez-Peralta, Judith
Nailes, Jennifer
Santos, Jaime
Ong-Lim, Anna
author_sort Perdrizet, Johnna
collection PubMed
description This communication seeks to address the questions of Dhere and colleagues in their letter on our study “Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) versus lower-valent alternatives in Filipino infants.” We hope to provide clarity on each of the three potential misunderstandings of our cost-effectiveness analysis that were raised by Dhere and colleagues.
format Online
Article
Text
id pubmed-9124259
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-91242592022-05-23 A Response to: Letter to the Editor Regarding “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants” Perdrizet, Johnna Horn, Emily K. Nua, Winniefer Perez-Peralta, Judith Nailes, Jennifer Santos, Jaime Ong-Lim, Anna Infect Dis Ther Letter This communication seeks to address the questions of Dhere and colleagues in their letter on our study “Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) versus lower-valent alternatives in Filipino infants.” We hope to provide clarity on each of the three potential misunderstandings of our cost-effectiveness analysis that were raised by Dhere and colleagues. Springer Healthcare 2022-04-26 2022-06 /pmc/articles/PMC9124259/ /pubmed/35474191 http://dx.doi.org/10.1007/s40121-022-00639-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Letter
Perdrizet, Johnna
Horn, Emily K.
Nua, Winniefer
Perez-Peralta, Judith
Nailes, Jennifer
Santos, Jaime
Ong-Lim, Anna
A Response to: Letter to the Editor Regarding “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
title A Response to: Letter to the Editor Regarding “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
title_full A Response to: Letter to the Editor Regarding “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
title_fullStr A Response to: Letter to the Editor Regarding “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
title_full_unstemmed A Response to: Letter to the Editor Regarding “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
title_short A Response to: Letter to the Editor Regarding “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
title_sort response to: letter to the editor regarding “cost-effectiveness of the 13-valent pneumococcal conjugate vaccine (pcv13) versus lower-valent alternatives in filipino infants”
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124259/
https://www.ncbi.nlm.nih.gov/pubmed/35474191
http://dx.doi.org/10.1007/s40121-022-00639-3
work_keys_str_mv AT perdrizetjohnna aresponsetolettertotheeditorregardingcosteffectivenessofthe13valentpneumococcalconjugatevaccinepcv13versuslowervalentalternativesinfilipinoinfants
AT hornemilyk aresponsetolettertotheeditorregardingcosteffectivenessofthe13valentpneumococcalconjugatevaccinepcv13versuslowervalentalternativesinfilipinoinfants
AT nuawinniefer aresponsetolettertotheeditorregardingcosteffectivenessofthe13valentpneumococcalconjugatevaccinepcv13versuslowervalentalternativesinfilipinoinfants
AT perezperaltajudith aresponsetolettertotheeditorregardingcosteffectivenessofthe13valentpneumococcalconjugatevaccinepcv13versuslowervalentalternativesinfilipinoinfants
AT nailesjennifer aresponsetolettertotheeditorregardingcosteffectivenessofthe13valentpneumococcalconjugatevaccinepcv13versuslowervalentalternativesinfilipinoinfants
AT santosjaime aresponsetolettertotheeditorregardingcosteffectivenessofthe13valentpneumococcalconjugatevaccinepcv13versuslowervalentalternativesinfilipinoinfants
AT onglimanna aresponsetolettertotheeditorregardingcosteffectivenessofthe13valentpneumococcalconjugatevaccinepcv13versuslowervalentalternativesinfilipinoinfants
AT perdrizetjohnna responsetolettertotheeditorregardingcosteffectivenessofthe13valentpneumococcalconjugatevaccinepcv13versuslowervalentalternativesinfilipinoinfants
AT hornemilyk responsetolettertotheeditorregardingcosteffectivenessofthe13valentpneumococcalconjugatevaccinepcv13versuslowervalentalternativesinfilipinoinfants
AT nuawinniefer responsetolettertotheeditorregardingcosteffectivenessofthe13valentpneumococcalconjugatevaccinepcv13versuslowervalentalternativesinfilipinoinfants
AT perezperaltajudith responsetolettertotheeditorregardingcosteffectivenessofthe13valentpneumococcalconjugatevaccinepcv13versuslowervalentalternativesinfilipinoinfants
AT nailesjennifer responsetolettertotheeditorregardingcosteffectivenessofthe13valentpneumococcalconjugatevaccinepcv13versuslowervalentalternativesinfilipinoinfants
AT santosjaime responsetolettertotheeditorregardingcosteffectivenessofthe13valentpneumococcalconjugatevaccinepcv13versuslowervalentalternativesinfilipinoinfants
AT onglimanna responsetolettertotheeditorregardingcosteffectivenessofthe13valentpneumococcalconjugatevaccinepcv13versuslowervalentalternativesinfilipinoinfants

Ejemplares similares